Biosimilars

Are they really safe?

June M McKoy, Frank J. Giles*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages61-73
Number of pages13
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume171
ISSN (Print)0927-3042

Fingerprint

Biosimilar Pharmaceuticals
Cost Savings
Safety
Research
Neoplasms

Keywords

  • Adverse events
  • Biosimilars
  • Cancer
  • Regulatory approval

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

McKoy, J. M., & Giles, F. J. (2019). Biosimilars: Are they really safe? In Cancer Treatment and Research (pp. 61-73). (Cancer Treatment and Research; Vol. 171). Springer International Publishing. https://doi.org/10.1007/978-3-319-43896-2_5
McKoy, June M ; Giles, Frank J. / Biosimilars : Are they really safe?. Cancer Treatment and Research. Springer International Publishing, 2019. pp. 61-73 (Cancer Treatment and Research).
@inbook{3a33b9436e3248ab97b5817e44ef9352,
title = "Biosimilars: Are they really safe?",
abstract = "An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.",
keywords = "Adverse events, Biosimilars, Cancer, Regulatory approval",
author = "McKoy, {June M} and Giles, {Frank J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43896-2_5",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "61--73",
booktitle = "Cancer Treatment and Research",

}

McKoy, JM & Giles, FJ 2019, Biosimilars: Are they really safe? in Cancer Treatment and Research. Cancer Treatment and Research, vol. 171, Springer International Publishing, pp. 61-73. https://doi.org/10.1007/978-3-319-43896-2_5

Biosimilars : Are they really safe? / McKoy, June M; Giles, Frank J.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 61-73 (Cancer Treatment and Research; Vol. 171).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Biosimilars

T2 - Are they really safe?

AU - McKoy, June M

AU - Giles, Frank J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.

AB - An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosimilars with different approaches within major regulatory agencies. We discuss some of the specific properties of biosimilars that merit attention in terms of optimizing their safety, delivering on appropriate related cost savings, and ensuring that appropriate premiums on innovative research are available to ensure ongoing progress in anticancer therapy.

KW - Adverse events

KW - Biosimilars

KW - Cancer

KW - Regulatory approval

UR - http://www.scopus.com/inward/record.url?scp=85058971584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058971584&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43896-2_5

DO - 10.1007/978-3-319-43896-2_5

M3 - Chapter

T3 - Cancer Treatment and Research

SP - 61

EP - 73

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -

McKoy JM, Giles FJ. Biosimilars: Are they really safe? In Cancer Treatment and Research. Springer International Publishing. 2019. p. 61-73. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-43896-2_5